Gender-affirming hormone therapy: effects on cardiovascular risk and vascular function
Endocrine Connections · 01.02.2025 · 14 (2)
DOI: 10.1530/ec-24-0222 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Connections, online erschienen am 22.11.2024. Verfasst von Kirsty A McGinley und 3 weiteren Autor:innen. Beteiligte Einrichtung: K A McGinley, School of Cardiovascular and Metabolic Health Sciences, University of Glasgow, Glasgow, UK. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Graphical abstract Gender-affirming hormone therapy and cardiovascular disease risk in transgender individuals. CIMT, carotid intima–media thickness. CVD, cardiovascular disease. FMD, flow-mediated dilatation. PWV, pulse wave velocity. TGM, transgender men. Created using BioRender.com. Abstract Background Gender-affirming hormone therapy (GAHT) is used in individuals with gender identity dysphoria to align their secondary sexual characteristics with their affirmed gender. We conducted a systematic review of the literature to explore the mechanisms regarding the effects of GAHT on the vasculature.
Methods
A literature search using PubMed, Embase, Scopus and LILACS was performed using search terms for GAHT, cardiovascular disease (CVD) risk and transgender. Studies were screened by two independent reviewers. Comparison to a cohort of transgender individuals naive or prior to GAHT or a cisgender population was required. Quality assessment was done using the relevant Critical Appraisal Skills Programme checklists.
Results
Out of 2,564 potentially eligible studies, 69 studies met the inclusion criteria. Studies provided evidence of beneficial changes in CVD risk profile, including reduced haemoglobin and pro-inflammatory markers, and atheroprotective changes in lipids in transgender women. In transgender men, there was evidence of negative changes in CVD risk profile, including atherogenic changes in lipids and increased haemoglobin, arterial stiffness and pro-inflammatory markers.
Conclusions
There is a paucity of research across non-traditional measures of CVD risk, which in combination with heterogeneous study design, loss of follow-up, low sample sizes and lack of diversity in age and ethnicity requires the results to be interpreted with caution. More evidence is required to elucidate the mechanisms behind the increased risk of CVD in the transgender population and determine whether GAHT is a contributing factor.
Autor:innen und Institutionen
- K A McGinley, School of Cardiovascular and Metabolic Health Sciences, University of Glasgow, Glasgow, UK.
- A K Lucas-Herald, School of Cardiovascular and Metabolic Health Sciences, University of Glasgow, Glasgow, UK.
- P Connelly, School of Cardiovascular and Metabolic Health Sciences, University of Glasgow, Glasgow, UK.
- C Delles, School of Cardiovascular and Metabolic Health Sciences, University of Glasgow, Glasgow, UK.
ORCID-Profile: Kirsty A McGinley, Angela K Lucas-Herald, Christian Delles
Zitieren
APA
McGinley, K. A., Lucas-Herald, A. K., Connelly, P., & Delles, C. (2025). Gender-affirming hormone therapy: effects on cardiovascular risk and vascular function. Endocrine Connections, 14(2). https://doi.org/10.1530/ec-24-0222
Vancouver
McGinley KA, Lucas-Herald AK, Connelly P, Delles C. Gender-affirming hormone therapy: effects on cardiovascular risk and vascular function. Endocrine Connections. 2025;14(2). doi:10.1530/ec-24-0222
BibTeX
@article{McGinley2025,
author = {McGinley, Kirsty A and Lucas-Herald, Angela K and Connelly, Paul and Delles, Christian},
title = {Gender-affirming hormone therapy: effects on cardiovascular risk and vascular function},
journal = {Endocrine Connections},
year = {2025},
volume = {14},
number = {2},
doi = {10.1530/ec-24-0222}
}
EUVIMED